J Korean Diabetes.  2011 Dec;12(4):194-197. 10.4093/jkd.2011.12.4.194.

Oral Antidiabetic Agents in Patients with Chronic Kidney Disease

Affiliations
  • 1Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea. khmcilyong@naver.com

Abstract

Diabetes mellitus is the leading cause of chronic kidney disease worldwide. At present, a variety of classes of oral hypoglycemic agents are available to improve glycemic control, including newer classes of drugs such as DPP-IV inhibitors. Decreased renal function with reduced glomerular filtration rate affects the choices, dosing, and monitoring of oral hypoglycemic agents, as some agents require dose adjustments in patients with chronic kidney disease and others are entirely contraindicated. This article reviews the clinical use of oral hypoglycemic agents, focusing on pharmacokinetic properties and dosing in patients with chronic kidney disease.

Keyword

Oral administration; Hypoglycemic agents; Chronic kidney failure

MeSH Terms

Administration, Oral
Diabetes Mellitus
Glomerular Filtration Rate
Humans
Hypoglycemic Agents
Kidney Failure, Chronic
Renal Insufficiency, Chronic
Hypoglycemic Agents

Reference

1. Task Force Team for Basic Statistical Study of Korean Diabetes Mellitus. Report of Task Force Team for Basic Statistical Study of Korean Diabetes Mellitus. Diabetes in Korea 2007. 1st ed.Seoul: Goldfishery;2007. p. 46.
2. Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin. 2007; 23:945–52.
Article
3. Chipkin SR. How to select and combine oral agents for patients with type 2 diabetes mellitus. Am J Med. 2005; 118(Suppl 5A):4S–13S.
Article
4. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002; 287:360–72.
5. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005; 65:385–411.
6. Reilly JB, Berns JS. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease. Semin Dial. 2010; 23:163–8.
Article
7. KDOQI. KDOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007; 49(2 Suppl 2):S12–154.
8. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011; 34:1431–7.
Article
9. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193–203.
10. Committee of Clinical Practice Guideline, Korean Diabetes Association. Treatment guideline for diabetes. 4th ed. J Korean Diabetes. 2011; 12(Suppl 1):65–72.
11. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011; 13:7–18.
Article
Full Text Links
  • JKD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr